Profound Medical Corp. (PROF): Cash & Equivalents
$59.72M
As of 2025-12-31
$38.27M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $59.72M | +8.8% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $54.91M | +109.5% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $26.21M | n/a | 2025-03-07, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Profound Medical Corp. (PROF) | 2025-12-31 | $59.72M | +8.8% |
| Biotricity Inc. (BTCY) | 2026-03-31 | $149.8K | -59.0% |
| Allurion Technologies, Inc. (ALUR) | 2025-12-31 | $5.41M | -64.8% |
| Vivos Therapeutics, Inc. (VVOS) | 2025-12-31 | $2.03M | -67.6% |
| Nephros Inc (NEPH) | 2025-12-31 | $5.40M | +43.6% |
| Sonoma Pharmaceuticals, Inc. (SNOA) | 2026-03-31 | $2.40M | -55.4% |
| Spectral AI, Inc. (MDAI) | 2025-12-31 | $15.40M | +196.2% |
| DarioHealth Corp. (DRIO) | 2025-12-31 | $21.80M | -21.5% |
| Baird Medical Investment Holdings Ltd (BDMD) | 2025-12-31 | $178.3K | -94.0% |
Compare PROF, BTCY, ALUR, VVOS side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗